Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: A case of successful switch to an alternative ALK inhibitor and systematic review of the literature

Lei Deng, Janaki N. Sharma, Elizabeth Ravera, Balazs Halmos, Haiying Cheng

Research output: Contribution to journalArticle


Alectinib can cause rare, but severe hypersensitivity. The cross-reactivity between different ALK inhibitors is unknown and desensitization is the only reported management. We hereby report the first case of severe delayed hypersensitivity developed in a lung cancer patient treated by alectinib, who was successfully managed by switching to brigatinib, another ALK inhibitor. The patient achieved excellent anti-tumor response to brigatinib. Our case provides an alternative and safe strategy in patients with alectinib-related hypersensitivity.

Original languageEnglish (US)
Pages (from-to)73-77
Number of pages5
JournalLung Cancer: Targets and Therapy
StatePublished - Jan 1 2018



  • Alectinib
  • Brigatinib

ASJC Scopus subject areas

  • Oncology

Cite this